{"doi":"10.17615/0vsf-xb80","title":"Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT","abstract":"The effectiveness of stem cell mobilization with G-CSF in lymphoma patients is suboptimal. We reviewed our institutional experience using chemomobilization with etoposide (VP-16; 375 mg/m2 on days +1 and +2) and G-CSF (5 μg/kg twice daily from day +3 through the final day of collection) in 159 patients with lymphoma. This approach resulted in successful mobilization (>2 × 106 CD34+ cells collected) in 94% of patients (83% within 4 apheresis sessions). Fifty-seven percent of patients yielded at least 5 × 106 cells in 2 days and were defined as good mobilizers. The regimen was safe with a low rate of rehospitalization. Average costs were $14 923 for good mobilizers and $27 044 for poor mobilizers (P<0.05). Using our data, we performed a ‘break-even’ analysis that demonstrated that adding two doses of Plerixafor to predicted poor mobilizers at the time of first CD34+ cell count would achieve cost neutrality if the frequency of good mobilizers were to increase by 21%, while the frequency of good mobilizers would need to increase by 25% if three doses of Plerixafor were used. We conclude that chemomobilization with etoposide and G-CSF in patients with lymphoma is effective, with future opportunities for cost-neutral improvement using novel agents.","journal":"UNC Libraries","year":2020,"id":112665,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9506,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":262408,"name":"Jonathan S. Serody","orcid":"0000-0003-4568-1092","position":1,"is_corresponding":false},{"id":533105,"name":"RK Goyal","orcid":"0000-0003-1632-036X","position":2,"is_corresponding":false},{"id":533106,"name":"Paul M. Armistead","orcid":"0000-0003-3983-5534","position":3,"is_corresponding":false},{"id":533107,"name":"James M. Coghill","orcid":"0000-0002-4736-0877","position":4,"is_corresponding":false},{"id":446664,"name":"Don A. Gabriel","orcid":null,"position":5,"is_corresponding":false},{"id":533108,"name":"Julia Whitley","orcid":"0000-0002-1452-6519","position":6,"is_corresponding":false},{"id":389600,"name":"Thomas C. Shea","orcid":null,"position":7,"is_corresponding":false},{"id":533777,"name":"P. M. Brown","orcid":null,"position":8,"is_corresponding":false},{"id":533778,"name":"Andrew Sharf","orcid":null,"position":9,"is_corresponding":false},{"id":520488,"name":"Stefanie Sarantopoulos","orcid":"0000-0003-4551-6687","position":10,"is_corresponding":false},{"id":533779,"name":"Amber N Essenmacher","orcid":null,"position":11,"is_corresponding":false},{"id":363961,"name":"William A. Wood","orcid":"0000-0001-7439-2543","position":12,"is_corresponding":false},{"id":533780,"name":"Robert Irons","orcid":null,"position":13,"is_corresponding":false},{"id":533104,"name":"Kamakshi V. Rao","orcid":"0000-0002-5621-2366","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-18T23:13:17.845093Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}